About this Journal Submit a Manuscript Table of Contents
PPAR Research
Volume 2012 (2012), Article ID 456529, 10 pages
http://dx.doi.org/10.1155/2012/456529
Review Article

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes

Division of Diabetic Complications, Baker IDI Heart and Diabetes Institute, P.O. Box 6492, Melbourne, VIC 8008, Australia

Received 9 September 2011; Revised 21 November 2011; Accepted 21 November 2011

Academic Editor: Brian Finck

Copyright © 2012 M. C. Thomas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPARδ: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at Publisher · View at Google Scholar · View at PubMed
  2. P. H. Groop, M. C. Thomas, J. L. Moran et al., “The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes,” Diabetes, vol. 58, no. 7, pp. 1651–1658, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. M. Stephenson, S. Kenny, L. K. Stevens, J. H. Fuller, and E. Lee, “Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes,” Diabetic Medicine, vol. 12, no. 2, pp. 149–155, 1995. View at Scopus
  4. A. I. Adler, R. J. Stevens, S. E. Manley, R. W. Bilous, C. A. Cull, and R. R. Holman, “Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64),” Kidney International, vol. 63, no. 1, pp. 225–232, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. B. M. Spiegelman, “PPAR-γ: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. H. S. Camp, O. Li, S. C. Wise et al., “Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone,” Diabetes, vol. 49, no. 4, pp. 539–547, 2000. View at Scopus
  8. Y. Kamijo, K. Hora, N. Tanaka et al., “Identification of functions of peroxisome proliferator-activated receptor α in proximal tubules,” Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1691–1702, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Ouali, F. Djouadi, C. Merlet-Bénichou, and J. Bastin, “Dietary lipids regulate β-oxidation enzyme gene expression in the developing rat kidney,” American Journal of Physiology, vol. 275, no. 5, pp. F777–F784, 1998. View at Scopus
  10. E. F. Johnson, C. N. A. Palmer, K. J. Griffin, and M. H. Hsu, “Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation,” The FASEB Journal, vol. 10, no. 11, pp. 1241–1248, 1996. View at Scopus
  11. R. Mukherjee, L. Jow, G. E. Croston, and J. R. Paterniti, “Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists,” Journal of Biological Chemistry, vol. 272, no. 12, pp. 8071–8076, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans,” American Journal of Physiology, vol. 273, no. 6, pp. F1013–F1022, 1997. View at Scopus
  13. S. A. Kliewer, B. M. Forman, B. Blumberg et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Inamoto, J. B. Shah, and A. M. Kamat, “Friend or foe? Role of peroxisome proliferator-activated receptor-γ in human bladder cancer,” Urologic Oncology, vol. 27, no. 6, pp. 585–591, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. K. Sato, A. Sugawara, M. Kudo, A. Uruno, S. Ito, and K. Takeuchi, “Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney,” Hypertension Research, vol. 27, no. 6, pp. 417–425, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Yang, D. E. Michele, J. Park et al., “Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney,” American Journal of Physiology, vol. 277, no. 6, pp. F966–F973, 1999. View at Scopus
  17. Y. T. Zhou, M. Shimabukuro, M. Y. Wang et al., “Role of peroxisome proliferator-activated receptor α in disease of pancreatic β cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8898–8903, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Joly, R. Roduit, M. L. Peyot et al., “Glucose represses PPARα gene expression via AMP-activated protein kinase but not via p38 mitogen-activated protein kinase in the pancreatic β-cell,” Journal of Diabetes, vol. 1, no. 4, pp. 263–272, 2009. View at Scopus
  19. R. Mishra, S. N. Emancipator, C. Miller, T. Kern, and M. S. Simonson, “Adipose differentiation-related protein and regulators of lipid homeostasis identified by gene expression profiling in the murine db/db diabetic kidney,” American Journal of Physiology, vol. 286, no. 5, pp. F913–F921, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. C. W. Park, H. W. Kim, S. H. Ko et al., “Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor α,” Diabetes, vol. 55, no. 4, pp. 885–893, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. U. Panchapakesan, C. A. Pollock, and X. M. Chen, “The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cells,” American Journal of Physiology, vol. 287, no. 3, pp. F528–F534, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. F. Zheng, A. Fornoni, S. J. Elliot et al., “Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation,” American Journal of Physiology, vol. 282, no. 4, pp. F639–F648, 2002. View at Scopus
  23. R. Rodríguez-Calvo, L. Serrano, T. Coll et al., “Activation of peroxisome proliferator-activated receptor β/δ inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-κB activity via extracellular signal-related kinase 1/2,” Diabetes, vol. 57, no. 8, pp. 2149–2157, 2008. View at Publisher · View at Google Scholar · View at PubMed
  24. J. Lepenies, M. Hewison, P. M. Stewart, and M. Quinkler, “Renal PPARγ mRNA expression increases with impairment of renal function in patients with chronic kidney disease,” Nephrology, vol. 15, no. 7, pp. 683–691, 2010. View at Scopus
  25. A. C. Calkin, S. Giunti, K. A. Jandeleit-Dahm, T. J. Allen, M. E. Cooper, and M. C. Thomas, “PPAR-α and γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2399–2405, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. C. W. Park, Y. Zhang, X. Zhang et al., “PPARα agonist fenofibrate improves diabetic nephropathy in db/db mic,” Kidney International, vol. 69, no. 9, pp. 1511–1517, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. S. Ren, C. Xin, K. F. Beck et al., “PPARα activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism,” Biochemical and Biophysical Research Communications, vol. 338, no. 4, pp. 1818–1824, 2005. View at Publisher · View at Google Scholar · View at PubMed
  28. X. Zhao and L. Y. Li, “PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats,” American Journal of Nephrology, vol. 28, no. 4, pp. 598–606, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. K. Isshiki, M. Haneda, D. Koya, S. Maeda, T. Sugimoto, and R. Kikkawa, “Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats,” Diabetes, vol. 49, no. 6, pp. 1022–1032, 2000. View at Scopus
  30. M. Fujii, R. Takemura, M. Yamaguchi et al., “Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats,” Metabolism, vol. 46, no. 9, pp. 981–983, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. R. E. Buckingham, K. A. Al-Barazanji, C. D. N. Toseland et al., “Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in zucker fatty rats,” Diabetes, vol. 47, no. 8, pp. 1326–1334, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. A. C. Calkin, J. M. Forbes, C. M. Smith et al., “Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1903–1909, 2005. View at Publisher · View at Google Scholar · View at PubMed
  33. A. C. Calkin, M. E. Cooper, K. A. Jandeleit-Dahm, and T. J. Allen, “Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation,” Diabetologia, vol. 49, no. 4, pp. 766–774, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. J. C. Ansquer, C. Foucher, S. Rattier, M. R. Taskinen, and G. Steiner, “Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS),” American Journal of Kidney Diseases, vol. 45, no. 3, pp. 485–493, 2005. View at Publisher · View at Google Scholar · View at PubMed
  35. A. Keech, R. J. Simes, P. Barter, et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” The Lancet, vol. 366, no. 9500, pp. 1849–1861, 2005.
  36. H. N. Ginsberg, M. B. Elam, L. C. Lovato et al., “Effects of combination lipid therapy in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 362, no. 17, pp. 1563–1574, 2010. View at Publisher · View at Google Scholar · View at PubMed
  37. Y. M. Smolders, A. E. Van Eeden, C. D. A. Stehouwer, R. N. M. Weijers, E. H. Slaats, and J. Silberbusch, “Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?” European Journal of Clinical Investigation, vol. 27, no. 12, pp. 997–1002, 1997.
  38. M. C. Thomas, M. Rosengård-Bärlund, V. Mills et al., “Serum lipids and the progression of nephropathy in type 1 diabetes,” Diabetes Care, vol. 29, no. 2, pp. 317–322, 2006.
  39. N. Tolonen, C. Forsblom, L. Thorn et al., “Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes,” Diabetologia, vol. 52, no. 12, pp. 2522–2530, 2009. View at Publisher · View at Google Scholar · View at PubMed
  40. H. M. Colhoun, P. H. Bennett, M. Lu, et al., “Risk factors for renal failure: the WHO multinational study of vascular disease in diabetes,” Diabetologia, vol. 44, supplement 2, pp. S46–S53, 2001.
  41. X. Z. Ruan, Z. Varghese, and J. F. Moorhead, “An update on the lipid nephrotoxicity hypothesis,” Nature Reviews Nephrology, vol. 5, no. 12, pp. 713–721, 2009. View at Publisher · View at Google Scholar · View at PubMed
  42. B. Vergès, “Diabetic dyslipidaemia: insights for optimizing patient management,” Current Medical Research and Opinion, vol. 21, supplement 1, pp. S29–S40, 2005. View at Publisher · View at Google Scholar · View at PubMed
  43. M. R. Taskinen, “Diabetic dyslipidaemia: from basic research to clinical practice,” Diabetologia, vol. 46, no. 6, pp. 733–749, 2003. View at Publisher · View at Google Scholar · View at PubMed
  44. L. Duvillard, E. Florentin, G. Lizard et al., “Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy,” Diabetes Care, vol. 26, no. 5, pp. 1540–1544, 2003. View at Publisher · View at Google Scholar
  45. G. W. Cockerill, T. Y. Huehns, A. Weerasinghe et al., “Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation,” Circulation, vol. 103, no. 1, pp. 108–112, 2001.
  46. D. T. Ashby, K. A. Rye, M. A. Clay, M. A. Vadas, J. R. Gamble, and P. J. Barter, “Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 9, pp. 1450–1455, 1998.
  47. J. Hulthe and B. Fagerberg, “Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study),” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 7, pp. 1162–1167, 2002. View at Publisher · View at Google Scholar
  48. S. J. Shin, J. H. Lim, S. Chung et al., “Peroxisome proliferator-activated receptor-α activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats,” Hypertension Research, vol. 32, no. 10, pp. 835–845, 2009. View at Publisher · View at Google Scholar · View at PubMed
  49. F. J. Gonzalez, “Recent update on the PPARα-null mouse,” Biochimie, vol. 79, no. 2-3, pp. 139–144, 1997. View at Publisher · View at Google Scholar
  50. Y. Hattori, S. Hattori, and K. Kasai, “Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells,” Hypertension, vol. 33, no. 4, pp. 943–948, 1999.
  51. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001. View at Publisher · View at Google Scholar · View at PubMed
  52. A. C. Calkin, M. E. Cooper, K. A. Jandeleit-Dahm, and T. J. Allen, “Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation,” Diabetologia, vol. 49, no. 4, pp. 766–774, 2006. View at Publisher · View at Google Scholar · View at PubMed
  53. K. Asaba, A. Tojo, M. L. Onozato et al., “Effects of NADPH oxidase inhibitor in diabetic nephropathy,” Kidney International, vol. 67, no. 5, pp. 1890–1898, 2005. View at Publisher · View at Google Scholar · View at PubMed
  54. W. A. Wilmer, C. L. Dixon, C. Hebert, L. Lu, and B. H. Rovin, “PPAR-α ligands inhibit H2O2-mediated activation of transforming growth factor-β1 in human mesangial cells,” Antioxidants and Redox Signaling, vol. 4, no. 6, pp. 877–884, 2002.
  55. M. Evans, R. A. Anderson, J. Graham et al., “Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus,” Circulation, vol. 101, no. 15, pp. 1773–1779, 2000.
  56. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at PubMed
  57. J. M. Forbes, M. T. Coughlan, and M. E. Cooper, “Oxidative stress as a major culprit in kidney disease in diabetes,” Diabetes, vol. 57, no. 6, pp. 1446–1454, 2008. View at Publisher · View at Google Scholar · View at PubMed
  58. B. K. Chacko, C. Reily, A. Srivastava et al., “Prevention of diabetic nephropathy in Ins2,” Biochemical Journal, vol. 432, no. 1, pp. 9–19, 2010. View at Publisher · View at Google Scholar · View at PubMed
  59. C. X. Yao, W. Y. Li, S. F. Zhang, S. F. Zhang, H. F. Zhang, and M. X. Zang, “Effects of doxorubicin and fenofibrate on the activities of NADH oxidase and citrate synthase in mice,” Basic and Clinical Pharmacology and Toxicology, vol. 109, no. 6, pp. 452–456, 2011. View at Publisher · View at Google Scholar · View at PubMed
  60. R. Krysiak, A. Gdula-Dymek, and B. Okopien, “Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia,” American Journal of Cardiology, vol. 107, no. 7, pp. 1010–e1, 2011. View at Publisher · View at Google Scholar · View at PubMed
  61. J. Tonelli, W. Li, P. Kishore et al., “Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes,” Diabetes, vol. 53, no. 6, pp. 1621–1629, 2004. View at Publisher · View at Google Scholar
  62. L. Li, N. Emmett, D. Mann, and X. Zhao, “Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy,” Experimental Biology and Medicine, vol. 235, no. 3, pp. 383–391, 2010. View at Publisher · View at Google Scholar · View at PubMed
  63. N. Marx, G. K. Sukhova, T. Collins, P. Libby, and J. Plutzky, “PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells,” Circulation, vol. 99, no. 24, pp. 3125–3131, 1999.
  64. N. Marx, N. Mackman, U. Schönbeck et al., “PPARα activators inhibit tissue factor expression and activity in human monocytes,” Circulation, vol. 103, no. 2, pp. 213–219, 2001.
  65. B. P. Neve, D. Corseaux, G. Chinetti et al., “PPARα agonists inhibit tissue factor expression in human monocytes and macrophages,” Circulation, vol. 103, no. 2, pp. 207–212, 2001.
  66. F. N. Ziyadeh and G. Wolf, “Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy,” Current Diabetes Reviews, vol. 4, no. 1, pp. 39–45, 2008. View at Publisher · View at Google Scholar
  67. G. Wolf, S. Chen, and F. N. Ziyadeh, “From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy,” Diabetes, vol. 54, no. 6, pp. 1626–1634, 2005. View at Publisher · View at Google Scholar
  68. J. J. Li, S. J. Kwak, D. S. Jung et al., “Podocyte biology in diabetic nephropathy,” Kidney International, vol. 72, no. 106, pp. S36–S42, 2007. View at Publisher · View at Google Scholar · View at PubMed
  69. M. W. Seiler, H. G. Rennke, M. A. Venkatachalam, and R. S. Cotran, “Pathogenesis of polycation induced alterations ('fusion') of glomerular epithelium,” Laboratory Investigation, vol. 36, no. 1, pp. 48–61, 1977.
  70. G. I. Welsh, L. J. Hale, V. Eremina et al., “Insulin signaling to the glomerular podocyte is critical for normal kidney function,” Cell Metabolism, vol. 12, no. 4, pp. 329–340, 2010. View at Publisher · View at Google Scholar · View at PubMed
  71. C. Zhu, S. Huang, Y. Yuan et al., “Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ,” American Journal of Pathology, vol. 178, no. 5, pp. 2020–2031, 2011. View at Publisher · View at Google Scholar · View at PubMed
  72. R. Lennon, G. I. Welsh, A. Singh et al., “Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1,” Diabetologia, vol. 52, no. 9, pp. 1944–1952, 2009. View at Publisher · View at Google Scholar · View at PubMed
  73. H. C. Yang, L. J. Ma, J. Ma, and A. B. Fogo, “Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis,” Kidney International, vol. 69, no. 10, pp. 1756–1764, 2006. View at Publisher · View at Google Scholar · View at PubMed
  74. A. Benigni, C. Zoja, S. Tomasoni et al., “Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-γ agonist: molecular mechanism of the antiproteinuric effect of pioglitazone,” Journal of the American Society of Nephrology, vol. 17, no. 6, pp. 1624–1632, 2006. View at Publisher · View at Google Scholar · View at PubMed
  75. T. M. E. Davis, R. Ting, J. D. Best et al., “Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study,” Diabetologia, vol. 54, no. 2, pp. 280–290, 2011. View at Publisher · View at Google Scholar · View at PubMed
  76. H. Wang, J. L. Deng, J. Yue, J. Li, and Y. B. Hou, “Prostaglandin E1 for preventing the progression of diabetic kidney disease,” Cochrane Database of Systematic Reviews, vol. 5, article CD006872, 2010.
  77. L. J. Ma, C. Marcantoni, M. F. Linton, S. Fazio, and A. B. Fogo, “Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats,” Kidney International, vol. 59, no. 5, pp. 1899–1910, 2001. View at Publisher · View at Google Scholar · View at PubMed
  78. H. C. Yang, S. Deleuze, Y. Zuo, S. A. Potthoff, L. J. Ma, and A. B. Fogo, “The PPARγ agonist pioglitazone ameliorates aging-related progressive renal injury,” Journal of the American Society of Nephrology, vol. 20, no. 11, pp. 2380–2388, 2009. View at Publisher · View at Google Scholar · View at PubMed
  79. P. A. Sarafidis, P. C. Stafylas, P. I. Georgianos, A. N. Saratzis, and A. N. Lasaridis, “Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis,” American Journal of Kidney Diseases, vol. 55, no. 5, pp. 835–847, 2010. View at Publisher · View at Google Scholar · View at PubMed
  80. C. A. Schneider, E. Ferrannini, R. DeFronzo, G. Schernthaner, J. Yates, and E. Erdmann, “Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease,” Journal of the American Society of Nephrology, vol. 19, no. 1, pp. 182–187, 2008. View at Publisher · View at Google Scholar · View at PubMed
  81. S. M. Herrmann, J. Ringel, J. G. Wang, J. A. Staessen, and E. Brand, “Peroxisome proliferator-activated receptor-γ2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) Study,” Diabetes, vol. 51, no. 8, pp. 2653–2657, 2002.
  82. S. De Cosmo, S. Prudente, O. Lamacchia et al., “PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies,” Nephrology Dialysis Transplantation, vol. 26, no. 12, pp. 4011–4016, 2011. View at Publisher · View at Google Scholar · View at PubMed
  83. A. Jorsal, L. Tarnow, M. Lajer et al., “The PPARγ2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy,” Molecular Genetics and Metabolism, vol. 94, no. 3, pp. 347–351, 2008. View at Publisher · View at Google Scholar · View at PubMed
  84. D. S. H. Bell, “β-Cell rejuvenation with thiazolidinediones,” American Journal of Medicine, vol. 115, no. 8, pp. 20–23, 2003. View at Publisher · View at Google Scholar
  85. P. H. Groop, C. Forsblom, and M. C. Thomas, “Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes,” Nature Clinical Practice, vol. 1, no. 2, pp. 100–110, 2005. View at Publisher · View at Google Scholar · View at PubMed
  86. S. Ohtomo, Y. Izuhara, S. Takizawa et al., “Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model,” Kidney International, vol. 72, no. 12, pp. 1512–1519, 2007. View at Publisher · View at Google Scholar · View at PubMed
  87. G. Chinetti, S. Lestavel, V. Bocher et al., “PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway,” Nature Medicine, vol. 7, no. 1, pp. 53–58, 2001. View at Publisher · View at Google Scholar · View at PubMed
  88. S. Efrati, S. Berman, E. Ilgiyeav, Z. Averbukh, and J. Weissgarten, “PPAR-γ activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats,” Nephron Experimental Nephrology, vol. 106, no. 4, pp. e107–e112, 2007. View at Publisher · View at Google Scholar · View at PubMed
  89. K. Goya, S. Sumitani, M. Otsuki et al., “The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells,” Journal of Diabetes and its Complications, vol. 20, no. 5, pp. 336–342, 2006. View at Publisher · View at Google Scholar · View at PubMed
  90. T. Rszer and M. Ricote, “PPARs in the renal regulation of systemic blood pressure,” PPAR Research, vol. 2010, Article ID 698730, 2010. View at Publisher · View at Google Scholar · View at PubMed
  91. A. Sugawara, A. Uruno, M. Kudo, K. Matsuda, C. W. Yang, and S. Ito, “Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease,” Endocrine Journal, vol. 57, no. 10, pp. 847–852, 2010. View at Publisher · View at Google Scholar
  92. A. Meirhaeghe and P. Amouyel, “Impact of genetic variation of PPARγ in humans,” Molecular Genetics and Metabolism, vol. 83, no. 1-2, pp. 93–102, 2004. View at Publisher · View at Google Scholar · View at PubMed
  93. M. Horiki, H. Ikegami, T. Fujisawa et al., “Association of Pro12Ala polymorphism of PPARγ gene with insulin resistance and related diseases,” Diabetes Research and Clinical Practice, vol. 66, supplement 1, pp. S63–S67, 2004. View at Publisher · View at Google Scholar · View at PubMed
  94. A. C. Calkin, J. M. Forbes, C. M. Smith et al., “Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1903–1909, 2005. View at Publisher · View at Google Scholar · View at PubMed
  95. A. Gumieniczek, “Effects of pioglitazone on hyperglycemia-induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals,” Experimental and Toxicologic Pathology, vol. 56, no. 4-5, pp. 321–326, 2005. View at Publisher · View at Google Scholar
  96. A. Gumieniczek, “Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits,” Life Sciences, vol. 74, no. 5, pp. 553–562, 2003. View at Publisher · View at Google Scholar
  97. L. Wilson-Fritch, A. Burkart, G. Bell et al., “Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone,” Molecular and Cellular Biology, vol. 23, no. 3, pp. 1085–1094, 2003. View at Publisher · View at Google Scholar
  98. T. Matsui, S. I. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, and S. Okuda, “Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation,” Biochemical and Biophysical Research Communications, vol. 398, no. 2, pp. 326–330, 2010. View at Publisher · View at Google Scholar · View at PubMed
  99. K. N. Lai, L. Y. Y. Chan, H. Guo, S. C. W. Tang, and J. C. K. Leung, “Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy,” Pediatric Nephrology, vol. 26, no. 2, pp. 257–266, 2011. View at Publisher · View at Google Scholar · View at PubMed
  100. T. Okada, J. Wada, K. Hida et al., “Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms,” Diabetes, vol. 55, no. 6, pp. 1666–1677, 2006. View at Publisher · View at Google Scholar · View at PubMed
  101. S. Ohga, K. Shikata, K. Yozai et al., “Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation,” American Journal of Physiology, vol. 292, no. 4, pp. F1141–F1150, 2007. View at Publisher · View at Google Scholar · View at PubMed
  102. C. Whiteside, H. Wang, L. Xia, S. Munk, H. J. Goldberg, and I. G. Fantus, “Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells,” Experimental Diabetes Research, vol. 2009, p. 910783, 2009.
  103. K. Sharma, S. RamachandraRao, G. Qiu et al., “Adiponectin regulates albuminuria and podocyte function in mice,” Journal of Clinical Investigation, vol. 118, no. 5, pp. 1645–1656, 2008. View at Publisher · View at Google Scholar · View at PubMed
  104. Y. Miyazaki, E. Cersosimo, C. Triplitt, and R. A. DeFronzo, “Rosiglitazone decreases albuminuria in type 2 diabetic patients,” Kidney International, vol. 72, no. 11, pp. 1367–1373, 2007. View at Publisher · View at Google Scholar · View at PubMed
  105. Y. Guan, C. Hao, D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005. View at Publisher · View at Google Scholar · View at PubMed
  106. U. Panchapakesan, C. Pollock, and S. Saad, “Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake,” Nephrology, vol. 14, no. 3, pp. 298–301, 2009. View at Publisher · View at Google Scholar
  107. Y. Matsushita, D. Ogawa, J. Wada et al., “Activation of peroxisome proliferator-activated receptor δ inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice,” Diabetes, vol. 60, no. 3, pp. 960–968, 2011. View at Publisher · View at Google Scholar · View at PubMed
  108. Y. J. Liang, S. A. Chen, and J. H. Jian, “Peroxisome proliferator-activated receptor δ downregulates the expression of the receptor for advanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice,” European Journal of Pharmaceutical Sciences, vol. 43, no. 1-2, pp. 65–70, 2011. View at Publisher · View at Google Scholar · View at PubMed
  109. L. R. Burch, L. A. Donnelly, A. S. F. Doney et al., “Peroxisome proliferator-activated receptor-δ genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research tayside study,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 4, pp. 1830–1837, 2010. View at Publisher · View at Google Scholar · View at PubMed
  110. E. M. Ooi, G. F. Watts, D. L. Sprecher, D. C. Chan, and P. H. Barrett, “Mechanism of action of a Peroxisome Proliferator-Activated Receptor (PPAR)-δ agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 10, pp. E1568–E1576, 2011. View at Publisher · View at Google Scholar · View at PubMed
  111. E. Letavernier, J. Perez, E. Joye et al., “Peroxisome proliferator-activated receptor β/δ exerts a strong protection from ischemic acute renal failure,” Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2395–2402, 2005. View at Publisher · View at Google Scholar · View at PubMed
  112. T. Miyata and C. Van Ypersele De Strihou, “Diabetic nephropathy: a disorder of oxygen metabolism?” Nature Reviews Nephrology, vol. 6, no. 2, pp. 83–95, 2010. View at Publisher · View at Google Scholar · View at PubMed
  113. X. Yang, S. Kume, Y. Tanaka et al., “GW501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice,” PLoS ONE, vol. 6, no. 9, article e25271, 2011. View at Publisher · View at Google Scholar · View at PubMed
  114. C. H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, “Transcriptional repression of atherogenic inflammation: modulation by PPARδ,” Science, vol. 302, no. 5644, pp. 453–457, 2003. View at Publisher · View at Google Scholar · View at PubMed
  115. Y. J. Liang, J. H. Jian, Y. C. Liu et al., “Advanced glycation end products-induced apoptosis attenuated by PPARδ activation and epigallocatechin gallate through NF-κB pathway in human embryonic kidney cells and human mesangial cells,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 5, pp. 406–416, 2010. View at Publisher · View at Google Scholar · View at PubMed